Pretreatment lymphocyte count predicts benefit from concurrent chemotherapy with radiotherapy in oropharyngeal cancer
AuthorsPrice, James M
Mistry, Hitesh B
Cheadle, Eleanor J
Illidge, Timothy M
Lee, Lip W
McPartlin, Andrew J
Prestwich, R. J. D.
Pritchard, D. J.
Sykes, Andrew J
West, Catharine M L
Thomson, David J
AffiliationDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Mancheste
MetadataShow full item record
AbstractPurpose: There is a need to refine the selection of patients with oropharyngeal squamous cell carcinoma (OPSCC) for treatment de-escalation. We investigated whether pretreatment absolute lymphocyte count (ALC) predicted overall survival (OS) benefit from the addition of concurrent chemotherapy to radical radiotherapy. Patients and methods: This was an observational study of consecutive OPSCCs treated by curative-intent radiotherapy, with or without concurrent chemotherapy (n = 791) with external, independent validation from a separate institution (n = 609). The primary end point was OS at 5 years. Locoregional control (LRC) was assessed using competing risk regression as a secondary end point. Previously determined prognostic factors were used in a multivariable Cox proportional hazards model to assess the prognostic importance of ALC and the interaction between ALC and cisplatin chemotherapy use. Results: Pretreatment ALC was prognostic for 5-year OS on multivariable analysis (hazard ratio [HR] 0.64; 95% CI, 0.42 to 0.98; P = .04). It also predicted benefit from the use of concurrent cisplatin chemotherapy, with a significant interaction between cisplatin chemotherapy and pretreatment ALC (likelihood ratio test, P = .04): higher ALC count reduced the 5-year OS benefit compared with radiotherapy alone (HR 2.53; 95% CI, 1.03 to 6.19; P = .043). This was likely driven by an effect on LRC up to 5 years (interaction subdistribution HR 2.29; 95% CI, 0.68 to 7.71; P = .094). An independent validation cohort replicated the OS (HR 2.53; 95% CI, 0.98 to 6.52; P = .055) and LRC findings (interaction subdistribution HR 3.43; 95% CI, 1.23 to 9.52; P = .018). Conclusion: For OPSCC, the pretreatment ALC is prognostic for OS and also predicts benefit from the addition of cisplatin chemotherapy to radiotherapy. These findings require prospective evaluation, and could inform the selection of good prognosis patients for a de-escalation trial.
CitationPrice JM, Mistry HB, Betts G, Cheadle EJ, Dixon L, Garcez K, et al. Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022.
JournalJournal of Clinical Oncology
- Pre-treatment absolute lymphocyte count predicts for improved survival in human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma.
- Authors: Kreinbrink PJ, Li J, Parajuli S, Wise-Draper TM, Choi DL, Tang AL, Takiar V
- Issue date: 2021 May
- Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy.
- Authors: Parmar A, Macluskey M, Mc Goldrick N, Conway DI, Glenny AM, Clarkson JE, Worthington HV, Chan KK
- Issue date: 2021 Dec 20
- The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
- Authors: Chen CC, Wang L, Lin JC, Jan JS
- Issue date: 2015 Mar
- Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer.
- Authors: Punjabi A, Barrett E, Cheng A, Mulla A, Walls G, Johnston D, McAleese J, Moore K, Hicks J, Blyth K, Denholm M, Magee L, Gilligan D, Silverman S, Qureshi M, Clinch H, Hatton M, Philipps L, Brown S, O'Brien M, McDonald F, Faivre-Finn C, Hiley C, Evison M
- Issue date: 2021 Aug
- Absolute lymphocyte count: a potential prognostic factor for Merkel cell carcinoma.
- Authors: Johnson ME, Zhu F, Li T, Wu H, Galloway TJ, Farma JM, Perlis CS, Turaka A
- Issue date: 2014 Jun